Retatrutide vs tirzepatide vs semaglutide: the three-way, read honestly

Three drugs dominate the incretin conversation, and they line up as a neat ladder of mechanism. Semaglutide pulls one hormonal lever, tirzepatide pulls two, and retatrutide pulls three. The weight-loss numbers climb in the same order — about 15%, 21% and 24% at the top doses. It is a tidy story, and it is mostly true. But the single most important thing to understand about these three agents is that they have never been compared in one trial, and one of them cannot be prescribed at all.

The mechanism ladder, rung by rung

The three agents differ by how many incretin-and-metabolic receptors a single peptide activates. Semaglutide is a GLP-1 receptor mono-agonist: one pathway, driving appetite suppression and insulin secretion. Tirzepatide adds the GIP receptor, making it a dual agonist — the extra incretin arm is the mechanistic reason many expected it to outperform semaglutide, a question taken up in our tirzepatide vs semaglutide review. Retatrutide adds a third target, the glucagon receptor, which is thought to raise energy expenditure and mobilize hepatic fat on top of the two incretin effects. Each added rung is a plausible reason to expect more weight loss — but mechanism predicts the direction of an effect, not its size.

The three headline numbers

In STEP 1, once-weekly semaglutide 2.4 mg produced a mean weight loss of about 14.9% at 68 weeks in adults with obesity and without diabetes.^[1] In SURMOUNT-1, tirzepatide at 15 mg reached roughly 20.9% at 72 weeks in a comparable population.^[2] In the retatrutide Phase 2 obesity trial, 338 adults received the triple agonist or placebo, and the 12 mg dose produced about 24.2% mean weight loss at 48 weeks.^[3] The ordering matches the mechanism ladder exactly — which is satisfying, and also the reason to be careful. A neat pattern is easy to over-read.

Why this is not a fair three-way race

Those three figures come from three different studies, run in different people, over different durations, at different phases of development. STEP 1 ran 68 weeks; SURMOUNT-1 ran 72; the retatrutide trial ran 48 and, notably, had not clearly plateaued when it ended — a detail we unpack in the retatrutide Phase 2 evidence review. Baseline weights, trial designs and dropout handling all differ. Lining the bars up side by side suggests the ranking is right; it does not prove the magnitudes are directly comparable.

The deeper asymmetry is regulatory. Semaglutide and tirzepatide are FDA-approved, backed by full Phase 3 programs and, in semaglutide's case, a large cardiovascular-outcomes dataset. Retatrutide is investigational: its numbers come from Phase 2, its Phase 3 program is ongoing, and it is approved nowhere. Efficacy and safety figures routinely shift when a drug moves into the larger, longer, more diverse populations of Phase 3 — so the 24.2% should be read as a promising early signal, not a settled property.

The three-way at a glance

What the drugs share

For all their differences, the three have a family resemblance. All are once-weekly subcutaneous injectables, and all share the incretin-class tolerability profile: nausea, vomiting and diarrhea that are common, dose-related and typically managed by slow dose escalation. The one head-to-head fact anywhere in this trio is between the two approved drugs — SURMOUNT-5 randomized tirzepatide against semaglutide at obesity doses and found tirzepatide produced greater weight loss.^[4] No such randomized comparison exists for retatrutide against either, which is exactly why the retatrutide vs tirzepatide comparison stays cross-trial.

The honest bottom line

Read as a mechanism story, the ladder holds: more receptors, more reported weight loss, in the order you would predict. Read as a clinical ranking, it is far shakier. Two of these drugs are approved, available and supported by Phase 3 outcomes data; the third is a mid-stage candidate whose numbers may move before — or if — it ever reaches the market. The trials also differed in design and population, so the magnitudes are not interchangeable. Treat retatrutide's edge as the strongest early signal published to date, and treat semaglutide and tirzepatide as the two drugs a patient can actually be prescribed today.